2024-518298-33-00招募中1 期
A phase I trial of IMA970A plus Montanide in combination with Durvalumab (anti-PD-L1) in patients with very early, early and intermediate stage of hepatocellular carcinoma after any standard treatments.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 10
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Luigi Buonaguro
Scientific
IRCCS Istituto Nazionale Tumori Fondazione Pascale
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
A Phase I/II clinical study of IMA970A plus CV8102 and Cyclophosphamide for patients with liver cancerVery early, early and intermediate stage hepatocellular carcinomaMedDRA version: 19.1Level: LLTClassification code 10049010Term: Carcinoma hepatocellularSystem Organ Class: 100000004864EUCTR2015-003389-10-ESIstituto Nazionale Tumori G. Pascale22
进行中（未招募）
1 期
A Phase I/II clinical study of IMA970A plus CV8102 and Cyclophosphamide for patients with liver cancerVery early, early and intermediate stage hepatocellular carcinomaMedDRA version: 20.0 Level: LLT Classification code 10049010 Term: Carcinoma hepatocellular System Organ Class: 100000004864EUCTR2015-003389-10-BEIstituto Nazionale Tumori G. Pascale40
进行中（未招募）
1 期
A Phase I/II clinical study of IMA970A plus CV8102 and Cyclophosphamide for patients with liver cancerVery early, early and intermediate stage hepatocellular carcinomaMedDRA version: 20.0Level: LLTClassification code 10049010Term: Carcinoma hepatocellularSystem Organ Class: 100000004864EUCTR2015-003389-10-DEIstituto Nazionale Tumori G. Pascale22
进行中（未招募）
1 期
A Phase I/II clinical study of IMA970A plus CV8102 and Cyclophosphamide for patients with liver cancerVery early, early and intermediate stage hepatocellular carcinomaMedDRA version: 21.1Level: LLTClassification code 10049010Term: Carcinoma hepatocellularSystem Organ Class: 100000004864EUCTR2015-003389-10-ITISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE22
已完成
1 期
Phase I study on the combination therapy of IMF-001 and MIS416 for the treatment of patients with NY-ESO-1 expressing malignant solid tumor.Malignant solid tumorJPRN-UMIN000008007Mie University Graduate School of Medicine12